Citius Oncology, Inc. (CTOR) vs Verrica Pharmaceuticals Inc. (VRCA)
A side-by-side comparison of Citius Oncology, Inc. and Verrica Pharmaceuticals Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CTOR
Citius Oncology, Inc.
$0.85HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
VRCA
Verrica Pharmaceuticals Inc.
$4.21HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — CTOR vs VRCA
growth of $100 · dividends reinvested · last 2yCTOR -92.4% (-72.4%/yr)VRCA -93.9% (-75.3%/yr)CTOR compounded faster over this window
CTOR VRCA
CTOR vs VRCA: by the numbers
- •CTOR is the larger company ($79M vs $72M market cap).
- •Both run net losses; VRCA's is the smaller (-102.84% vs -648.32% net margin).
Metrics side by side
Valuation
| Metric | CTOR | VRCA |
|---|---|---|
| Forward P/E | 8.50 | N/A |
| P/S ratio | 11.12 | 2.39 |
| P/B ratio | 1.96 | 16.79 |
Profitability
| Metric | CTOR | VRCA |
|---|---|---|
| Gross margin | 0.00% | 85.89% |
| Operating margin | 0.00% | -33.56% |
| Net margin | -648.32% | -102.84% |
| ROE | -114.06% | -724.01% |
| ROIC | -88.72% | -207.23% |
Growth (annualized)
| Metric | CTOR | VRCA |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 20.37% |
| Total return CAGR (5Y) | N/A | -48.68% |
Go deeper
Dig into the metrics
Citius Oncology ROEVerrica Pharmaceuticals ROECitius Oncology operating marginVerrica Pharmaceuticals operating marginCitius Oncology revenue growthVerrica Pharmaceuticals revenue growthCitius Oncology free cash flowVerrica Pharmaceuticals free cash flow
Citius Oncology & Verrica Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.